Biomea Fusion, Inc. (BMEA) Discusses Menin Inhibition Mechanism and Therapeutic Potential in Diabetes Transcript

PresentationMichael KingRodman & Renshaw Research Okay. All right. So then we can begin. Sorry about all the confusion everybody. We're going to kick it off right away in the interest of time. So we're pleased to be joined by the management from Biomea, including a welcome late addition Mick Hitchcock, Interim CEO; Ramses Erdtmann, Founder, Chief Operating Officer and President; and finally, Steve Morris, who is the Chief Development Officer. So I'm just going to make a couple of opening remarks, and we'll ...